Free cash flow of $51.8M in 2026Q3 (34.8% margin) following a 60.8% margin in 2025Q4 suggests strong cash generation, but operating cash flow to net income ratios ranging from 1.2x to 3.9x and working capital swings from a $11.0M outflow to a $42.7M inflow indicate conversion remains highly timing-dependent.
Cellebrite DI Ltd. (CLBT) cash flow statement — 7-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 |
|---|
| Cash from Operations | 176.28M | 168.96M | 132.17M | 102.06M | 20.58M | 36.05M | 66.51M | 16.13M |
| Operating CF Margin % | - | 35.52% | 32.94% | 31.39% | 7.6% | 14.64% | 34.12% | 9.39% |
| Operating CF Growth % | 43.93% | 27.83% | 29.51% | 395.98% | -42.92% | -45.79% | 312.26% | - |
| Net Income | 65.23M | 78.33M | -283.01M | -81.1M | 120.81M | 71.4M | 5.78M | -1.88M |
| Depreciation & Amortization | 29.2M | 11.87M | 10.61M | 10.01M | 9.19M | 7.01M | 5.88M | 4.08M |
| Stock-Based Compensation | 29.83M | 0 | 30.57M | 19M | 13.71M | 6.48M | 7.27M | 12.76M |
| Deferred Taxes | 1.2M | 75K | -4.01M | 5.13M | -2.39M | -1.64M | -2.82M | -1.67M |
| Other Non-Cash Items | 21.36M | 36.67M | 335.96M | 110.5M | -117.92M | -67.87M | 689K | 131K |
| Working Capital Changes | 29.46M | 42.02M | 42.05M | 38.52M | -2.82M | 20.68M | 49.71M | 2.71M |
| Change in Receivables | -30.11M | -15.78M | -5.83M | 2.27M | -12.88M | -1.96M | -19.73M | -12.22M |
| Change in Inventory | 1.45M | 1.63M | 982K | 243K | -3.68M | -1.8M | -693K | 794K |
| Change in Payables | 13.16M | 9.19M | 2.75M | 3.69M | -5.47M | 4.24M | -1.43M | 974K |
| Cash from Investing | -251.04M | -268.25M | -149.47M | -22.54M | -91.23M | 45.23M | -6.45M | -46.72M |
| Capital Expenditures | -30.47M | -13.22M | -8.57M | -5.23M | -6.9M | -5.11M | -6.18M | -6.21M |
| CapEx % of Revenue | 5.67% | 2.78% | 2.14% | 1.61% | 2.55% | 2.08% | 3.17% | 3.61% |
| Acquisitions | -162.73M | -147.46M | -2.75M | 0 | 0 | -20M | -15.05M | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | -22.74M | 861K | -2.04M | -2.69M | -2.19M | -3M | 0 | -40.51M |
| Cash from Financing | 16.66M | 29.64M | 20.65M | 21.77M | 13.97M | -68.4M | -8.59M | 75.54M |
| Debt Issued (Net) | 4.58M | 4.58M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 12.08M | 25.05M | 0 | 0 | 0 | 0 | -85K | 100.4M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | -100M | -10M | -25M |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -85K | -808K |
| Other Financing | 0 | 0 | 20.65M | 21.77M | 13.97M | 31.6M | 1.49M | 141K |
| Net Change in Cash | -58.31M | -67.2M | 2.14M | 101.87M | -58.33M | 12.13M | 52.16M | 44.88M |
| Free Cash Flow | 161.43M | 155.73M | 121.56M | 94.14M | 11.49M | 27.94M | 60.33M | 9.92M |
| FCF Margin % | 30.05% | 32.74% | 30.3% | 28.96% | 4.25% | 11.35% | 30.95% | 5.77% |
| FCF Growth % | 16.04% | 28.11% | 29.13% | 719.18% | -58.87% | -53.69% | 507.91% | - |
| FCF per Share | 0.63 | 0.62 | 0.58 | 0.50 | 0.06 | 0.17 | 0.32 | 0.05 |
| FCF Conversion (FCF/Net Income) | 2.47x | 2.16x | -0.47x | -1.26x | 0.17x | 0.50x | 11.50x | -8.60x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 4.62M | 0 | 7.71M | 10.05M | 9.05M | 8.16M | 2.91M | 3M |
Quick answers to the most common questions about buying CLBT stock.
Cellebrite DI Ltd. (CLBT) generated $169.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Cellebrite DI Ltd. (CLBT) generated $155.7M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Cellebrite DI Ltd. (CLBT) spent $13.2M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
Key Metrics
Top Statement Risk
Volatile quarterly cash conversion
Cash Conversion Swings Obscure Earnings Quality
Based on reported quarterly figures, CLBT's operating cash flow to net income ratio ranged from roughly 1.2x to 3.9x across recent periods, with negative ratios in 2024 when net income was negative, indicating highly uneven conversion.
The 2026Q3 operating cash flow of $56.6M against net income of $26.7M produced a ratio of 2.12x, which appears strong but may reflect working capital timing rather than structurally higher earnings quality. The 2024Q3 net loss of $207.1M, largely unexplained within the supplied data, makes historical conversion ratios difficult to interpret, and investors should monitor whether non-cash items such as stock-based compensation of $15.4M in the latest quarter are masking the underlying cash profile.
Free Cash Flow Margins Volatile Despite Scale
As reported in quarterly statements, CLBT's free cash flow margin moved between roughly 11% and 61% over the last ten quarters, with the 60.8% peak in 2025Q4 coinciding with a large working capital inflow.
The 2025Q4 free cash flow of $78.3M appears heavily dependent on a $42.7M working capital contribution and an acquisition outflow of $147.5M in the same period, suggesting the figure may not be representative of run-rate generation. Excluding such timing effects, the more typical range of roughly 11% to 26% in recent quarters implies moderate, not robust, cash generation that warrants continued monitoring.
Capital Intensity Remains Light and Stable
Based on reported figures, CLBT's capital expenditure has consistently run between 1.7% and 8.9% of revenue, with the higher 2026Q1 and 2026Q2 readings reflecting a temporary step-up relative to 2024 and 2025 levels.
The low absolute capex base, typically under $5M per quarter, is consistent with a software-weighted model in which R&D rather than physical plant drives investment. The recent elevation to roughly $10M to $12M per quarter in 2026 may indicate infrastructure or capitalized development spending, and whether this persists would materially affect free cash flow conversion.
Working Capital Drives Quarterly Cash Timing
According to reported cash flow statements, CLBT's working capital change swung from a $11.0M outflow in 2026Q2 to a $42.7M inflow in 2025Q4, indicating that quarterly cash generation is heavily influenced by billing and collection timing.
Large swings in working capital are consistent with multi-year subscription billing and government procurement cycles, where deferred revenue can inflate a single period's cash flow. Investors should monitor contract liability balances to distinguish genuine demand strength from timing-driven collections that may reverse in subsequent quarters.
Stock Compensation Bridges Earnings and Cash
As reported in the income and cash flow statements, CLBT's stock-based compensation reached $15.4M in 2026Q3 and $14.4M in 2026Q1, representing a material non-cash add-back that may flatter operating cash flow relative to economic earnings.
Because stock-based compensation is added back to operating cash flow, a portion of reported cash generation reflects equity dilution rather than cash retained by the business. Analysts should evaluate free cash flow net of SBC to assess whether the reported margin profile reflects durable economic value creation or is partially supported by compensation structures that transfer value to shareholders over time.